CG Oncology, Inc. financial data

Symbol
CGON on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
400 Spectrum Center Drive, Suite 2040, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.65K %
Debt-to-equity 3.41 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.6M shares
Common Stock, Shares, Outstanding 67.5M shares
Common Stock, Value, Issued 7K USD
Weighted Average Number of Shares Outstanding, Basic 67.1M shares +1432%
Weighted Average Number of Shares Outstanding, Diluted 67.1M shares +1432%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19.6M USD +67.2%
General and Administrative Expense 8.72M USD +276%
Operating Income (Loss) -28.3M USD -101%
Nonoperating Income (Expense) 7.89M USD +247%
Net Income (Loss) Attributable to Parent -20.4M USD -73.4%
Earnings Per Share, Basic -0.3 USD/shares +92.5%
Earnings Per Share, Diluted -0.3 USD/shares +92.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.4M USD
Marketable Securities, Current 497M USD
Assets, Current 552M USD
Property, Plant and Equipment, Net 63K USD
Operating Lease, Right-of-Use Asset 275K USD
Other Assets, Noncurrent 53K USD
Assets 552M USD
Accounts Payable, Current 4.08M USD
Liabilities, Current 15.6M USD
Operating Lease, Liability, Noncurrent 71K USD
Liabilities 15.7M USD
Retained Earnings (Accumulated Deficit) -186M USD
Stockholders' Equity Attributable to Parent 537M USD
Liabilities and Equity 552M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26M USD -226%
Net Cash Provided by (Used in) Financing Activities 403M USD
Net Cash Provided by (Used in) Investing Activities -307M USD -291%
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 67.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 69.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.4M USD +323%
Operating Lease, Liability 296K USD
Payments to Acquire Property, Plant, and Equipment 12K USD
Lessee, Operating Lease, Liability, to be Paid 299K USD
Operating Lease, Liability, Current 225K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 52K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 187K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD
Operating Lease, Payments 60K USD +1.7%
Additional Paid in Capital 723M USD
Depreciation, Depletion and Amortization 4K USD 0%
Share-based Payment Arrangement, Expense 2.65M USD +572%